CSLLY News and Press, CSL Ltd ADR From 08/02/22

All regulatory clearances received for the acquisition of Vifor Pharma AG Settlement of the offer is scheduled for 9 August 2022 Seasoned biopharma executive, Hervé Gisserot, designated to lead the business as General Manager upon settlement of the offer ...

Seqirus Begins Shipping Portfolio of Innovative Influenza Vaccines for the 2022/23 U.S. Season PR Newswire This year marks the first full season that Seqirus' portfolio of innovative influenza vaccines provides a differentiated vaccine option for people of all ages w...

Seqirus, a unit of Australian biotech CSL Limited (OTCPK:CSLLY) (OTCPK:CMXHF), announced that a group of independent experts of the U.S. CDC added its Fluad Quadrivalent shot as a preferentially recommended seasonal influenza vaccine for those aged 65 years and older. The decision of the CDC&...

CDC Advisory Committee Includes FLUAD® QUADRIVALENT as a Preferentially Recommended Influenza Vaccine for Adults 65 and Older PR Newswire ACIP recommends adults 65 years of age and older receive an enhanced flu vaccine, such as FLUAD ® QUADRIVAL...

Acclaimed Photographer Rankin and CSL Behring Team Up to Launch 'Portraits of Progress', an Exhibition Chronicling the Past, Present and Future of Life with Hemophilia PR Newswire Rankin's first in-person U.S. exhibit in three years showcases portraits and personal s...

Seqirus Completes $156 Million Expansion to Holly Springs Manufacturing Facility, Optimizing Global Manufacturing Capabilities for Seasonal and Pandemic Influenza Vaccines PR Newswire SUMMIT, N.J. , June 6, 2022 /PRNewswire/ -- Seqirus, a global leader in...

Seqirus' Holly Springs Manufacturing Facility Designated by U.S. Government as Pandemic Ready PR Newswire Seqirus is officially recognized by the U.S. government as having successfully established domestic manufacturing capability for innovative cell-based season...

The U.S. Food and Drug Administration (FDA) granted priority review to uniQure (NASDAQ:QURE) and CSL's (OTCPK:CSLLY) gene therapy etranacogene dezaparvovec (EtranaDez) to treat hemophilia B. The FDA accepted to review a biologics license application (BLA) submitted by CSL Behring, a...

FDA Accepts CSL Behring's Biologics License Application for Etranacogene Dezaparvovec for Priority Review PR Newswire -- If approved, etranacogene dezaparvovec would be the first gene therapy option for people living with hemophilia B -- This milestone underscores CS...

Polen Capital is a high-conviction growth investment manager. We scour the globe in search of the highest quality, sustainable companies to invest in. Over the first quarter of 2022, the Polen International Growth Composite Portfolio returned -13.94% gross and -14.17% net of fees, res...